Roccaro et al. uncovered CXCL12 and CXCR4 as putative targets to halt MM evolution and extramedullary dissemination in animal models [28, 145], indicating broad potential consequences on adhesion-mediated MM dissemination [29, 101, 146] and drug resistance, as in other solid and haematological malignancies [147–149] and prompt clinical validation [150]. This evidence concerns the gene CXCR4 and Miyoshi myopathy.